Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03630991 · ClinicalTrials.gov registry record · Phase 1

Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy

A Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndrome, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
Phase 1
Development phase
58
Enrollment target
1
Study location

NCT03630991 is a Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndrome that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 58 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (50% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03630991, a Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndrome, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
Phase 1
Development phase
58 participants
Enrollment target
1
Study location

Study Summary

This phase I trial studies the side effects and best dose of edetate calcium disodium or succimer in treating patients with acute myeloid leukemia or myelodysplastic syndrome undergoing chemotherapy. Edetate calcium disodium or succimer may help to lower the level of metals found in the bone marrow and blood and may help to control the disease and/or improve response to chemotherapy.

Conditions Studied

Acute Myeloid Leukemia Myelodysplastic Syndrome Recurrent Acute Myeloid Leukemia Myeloproliferative Neoplasm Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome Myelodysplastic/Myeloproliferative Neoplasm High Risk Myelodysplastic Syndrome Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive Chronic Myelogenous Leukemia, BCR-ABL1 Positive Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Interventions

  • DRUG Edetate Calcium Disodium
  • DIETARY_SUPPLEMENT Multivitamin
  • DRUG Succimer

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 58 participants
Start Date 2018-10-11
Est. Completion 2027-04-30
Phase Phase 1

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03630991

The ClinicalTrials.gov registry entry for NCT03630991 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (50% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Edetate Calcium Disodium is the first listed.

NCT03630991 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT03630991 about?

NCT03630991 is a clinical study titled "Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy". This phase I trial studies the side effects and best dose of edetate calcium disodium or succimer in treating patients with acute myeloid leukemia or myelodysplastic syndrome undergoing chemotherapy. Edetate calcium disodium or succimer may help to lower the level of metals found in the bone marrow ...

What is the current status of trial NCT03630991?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2018-10-11. Estimated completion is 2027-04-30.

What conditions does trial NCT03630991 study?

This clinical trial studies the following conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Myeloproliferative Neoplasm, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome.

What interventions are being tested in trial NCT03630991?

The interventions under investigation include: Edetate Calcium Disodium (DRUG), Multivitamin (DIETARY_SUPPLEMENT), Succimer (DRUG).

Who is sponsoring clinical trial NCT03630991?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03630991 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Myeloid Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acute Myeloid Leukemia

All registered trials for this condition

Myelodysplastic Syndrome

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.